Menu

Probing Down Syndrome with Mini Brains

Researchers create cerebral organoids using induced pluripotent stem cells from patient skin cells and characterize protein-expression changes linked to cognitive impairment.

Oct 20, 2015
Bob Grant

WIKIMEDIA, NATIONAL HUMAN GENOME RESEARCH INSTITUTEInduced pluripotent stem cells (iPSCs) grown from the skin cells of a person with Down syndrome are helping researchers grow cerebral organoids and track protein expression in an effort to better understand the disorder on a cellular and molecular level. University of Colorado Boulder postdoc Tristan McClure-Begley and his colleagues sought to better understand the neurological and developmental changes that occur in people with a third copy of chromosome 21, the unifying pathological feature of Down syndrome. “That third copy of chromosome 21 influences all aspects of embryonic development, including critical steps during brain development,” McClure-Begley said in a statement. “But we’ve had trouble identifying exactly why the extra chromosome has such widespread effects, partly because we’ve lacked good human tissue models of Down syndrome.”

So McClure-Begley and his colleagues took a fibroblast from a single Down syndrome patient, coaxed it into becoming two iPSC lines, and then reprogrammed those cells into neural progenitor cells that self-organized into cerebral tissue in vitro. “So we get a window into what an individual central nervous system development looked like from a cellular and molecular level,” he said during a Monday (October 19) press conference at the Society for Neuroscience (SfN) annual meeting held in Chicago.

The researchers found that protein expression did not follow a simple 1:1 ratio with the extra genes on the triplicate chromosome 21 leading to a proportional increase in proteins expressed. “Rather, there’s a complex change, where some proteins are upregulated, some proteins are downregulated—all reflecting a general disturbance in signaling,” McClure-Begley said. Many of the perturbed proteins were involved in early neurogenesis and cell cycle regulation, among other functions.

Earlier this year, researchers in Germany reported similar success growing cerebral organoids from iPSCs derived from skin cells of people with autism.

McClure-Begley added that his group plans to generate as many organoids from Down syndrome patients as possible in order characterize protein-expression profiles across the spectrum of the disorder, from mild to severe. “We can start observing . . . the discrete factors in their genome not on chromosome 21 that can influence the severity of their clinical presentation of Down syndrome,” he said. “By doing that, it’s our hope that we will actually be capable of then correlating clinical severity with a molecular signature from these tissues, thereby informing our ability to come up with tailored, personalized treatments to improve quality of life.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.